EYPT Stock Analysis: Buy, Sell, or Hold?
EYPT - EyePoint Pharmaceuticals, Inc. Common Stock
$5.32
-0.08 (-1.48%)
▼
5d:
-63.93%
30d:
-57.34%
90d:
-58.37%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Aug 17, 2026 at $4.53 · last confirmed Aug 21, 2026
Strength: 9.4/10
Get Alerted When EYPT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: EYPT is down 63.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: EYPT is down 63.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: EYPT is currently trading at $5.32, which is considered oversold relative to its 30-day fair value range of $8.82 to $14.57.
Technical Outlook: Technically, EYPT is in a downtrend. Immediate support is located at $3.95, while resistance sits at $14.76.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $27.36 (+414.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, EYPT is in a downtrend. Immediate support is located at $3.95, while resistance sits at $14.76.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $27.36 (+414.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$8.82 -
$14.57
Company Quality Score
44/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: Trading 414.4% below Wall St target ($27.36)
- WARNING: Composite score 44/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$8.82 -
$14.57
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.95
Resistance Level
$14.76
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.92
Wall Street Target
$27.36
(+414.4%)
Revenue Growth (YoY)
161.7%
Share & Embed Analysis
Last updated: August 23, 2026 8:12 PM ET
Data refreshes hourly during market hours. Next update: 9:12 PM
Data refreshes hourly during market hours. Next update: 9:12 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EYPT showing a specific setup today?
Insider Activity (6 Months)
1
Buys
1
Sells
0
Net
INSIDERS SELLING
Recent Transactions
Ramiro Ribeiro
SELL
2437 shares
2026-04-17
Jay S Duker
BUY
1500 shares
2026-03-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 50 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$840 | 34 SELL |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$281 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$127 | 41 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 66 BUY |
